{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"6","value":"2.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"Kaplan-Meier method was used. The log-rank test was performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model was used to include multiple covariates in the time-to-event analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Akt inhibitor MK2206 200 mg orally once a week, repeats every 28 days for up to 12 courses.","id":"OG000","title":"Akt Inhibitor MK2206"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From treatment start date until the date of first documented progression or date of death from any cause, whichever came first.","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}